{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:50Z","timestamp":1786118870039,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1097\/hjh.0b013e3282257145","type":"journal-article","created":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T03:01:27Z","timestamp":1186369287000},"page":"1967-1973","source":"Crossref","is-referenced-by-count":23,"title":["Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study"],"prefix":"10.1097","volume":"25","author":[{"given":"Vivencio","family":"Barrios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Calder\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa","family":"Navarro-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gonz\u00e1lez-Pedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onofre","family":"Vegazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-29-20210208","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"2003 European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension.","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"R3-29-20210208","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"322","author":"Levy","year":"1990","journal-title":"N Engl J Med"},{"key":"R4-29-20210208","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/01.CIR.97.1.48","article-title":"Prognostic significance of serial changes in left ventricular mass in essential hypertension","volume":"97","author":"Verdecchia","year":"1998","journal-title":"Circulation"},{"key":"R5-29-20210208","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/01.CIR.0000083724.28630.C3","article-title":"Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The LIFE Study","volume":"108","author":"Okin","year":"2003","journal-title":"Circulation"},{"key":"R6-29-20210208","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1001\/jama.292.19.2343","article-title":"Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of mayor cardiovascular events","volume":"292","author":"Okin","year":"2004","journal-title":"JAMA"},{"key":"R7-29-20210208","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0895-7061(03)01018-5","article-title":"Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis","volume":"16","author":"Verdecchia","year":"2003","journal-title":"Am J Hypertens"},{"key":"R8-29-20210208","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.HYP.0000133249.28773.d7","article-title":"Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project","volume":"44","author":"Schneider","year":"2004","journal-title":"Hypertension"},{"key":"R9-29-20210208","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.HYP.23.5.587","article-title":"Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression","volume":"23","author":"Everett","year":"1994","journal-title":"Hypertension"},{"key":"R10-29-20210208","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.HYP.35.1.313","article-title":"Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells","volume":"35","author":"Yamakawa","year":"2000","journal-title":"Hypertension"},{"key":"R11-29-20210208","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0895-7061(00)01257-7","article-title":"Left ventricular hypertrophy and angiotensin II antagonists","volume":"14","author":"Dahlof","year":"2001","journal-title":"Am J Hypertens"},{"issue":"Suppl 1","key":"R12-29-20210208","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J Hum Hypertens"},{"key":"R13-29-20210208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"R14-29-20210208","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/00004872-200211000-00030","article-title":"Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (Match) study","volume":"20","author":"Cuspidi","year":"2002","journal-title":"J Hypertens"},{"key":"R15-29-20210208","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"R16-29-20210208","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/00004872-200106000-00023","article-title":"Regression of left ventricular hypertrophy in human hypertension with irbesartan","volume":"19","author":"Malmqvist","year":"2001","journal-title":"J Hypertens"},{"key":"R17-29-20210208","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/080370500439191","article-title":"Efficacy and tolerability of candesartan cilexetil in special patient groups","volume":"1","author":"Trenkwalder","year":"2000","journal-title":"Blood Press Suppl"},{"key":"R18-29-20210208","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1254\/jjp.76.185","article-title":"A novel angiotensin II-receptor antagonist, 606A, induces regression of cardiac hypertrophy, augments endothelium-dependent relaxation and improves renal function in stroke-prone spontaneously hypertensive rats","volume":"76","author":"Hashimoto","year":"1998","journal-title":"Jpn J Pharmacol"},{"key":"R19-29-20210208","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/080370500439218","article-title":"Preserving target-organ function with candesartan cilexetil in patients with hypertension","volume":"1","author":"Zannad","year":"2000","journal-title":"Blood Press Suppl"},{"key":"R20-29-20210208","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1253\/circj.66.993","article-title":"Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease","volume":"66","author":"Isobe","year":"2002","journal-title":"Circulation"},{"key":"R21-29-20210208","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2165\/00003495-200262080-00016","article-title":"Candesartan cilexetil: an update of its use in essential hypertension","volume":"62","author":"Easthope","year":"2002","journal-title":"Drugs"},{"key":"R22-29-20210208","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/0735-1097(92)90376-X","article-title":"Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product","volume":"20","author":"Molloy","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"R23-29-20210208","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.HYP.0000135249.66192.30","article-title":"New gender-specific partition values for ECG criteria of left ventricular hypertrophy. Recalibration against cardiac MRI","volume":"44","author":"Alfakih","year":"2004","journal-title":"Hypertension"},{"key":"R24-29-20210208","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.HYP.32.6.989","article-title":"Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study","volume":"32","author":"Dahlof","year":"1998","journal-title":"Hypertension"},{"key":"R25-29-20210208","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0735-1097(94)00371-V","article-title":"Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products","volume":"25","author":"Okin","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"R26-29-20210208","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R27-29-20210208","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0002-8703(49)90562-1","article-title":"The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads","volume":"37","author":"Sokolow","year":"1949","journal-title":"Am Heart J"},{"key":"R28-29-20210208","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0735-1097(85)80115-7","article-title":"Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria","volume":"6","author":"Casale","year":"1985","journal-title":"J Am Coll Cardiol"},{"key":"R29-29-20210208","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/01.CIR.75.3.565","article-title":"Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings","volume":"75","author":"Casale","year":"1987","journal-title":"Circulation"},{"key":"R30-29-20210208","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1161\/01.HYP.31.4.937","article-title":"Time-voltage area of the 12-lead electrocardiogram. Detection of left ventricular hypertrophy","volume":"31","author":"Okin","year":"1998","journal-title":"Hypertension"},{"key":"R31-29-20210208","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00059-006-2819-5","article-title":"Ventricular hypertrophy and hypertension: prognostic elements and implications for management","volume":"31","author":"Krauser","year":"2006","journal-title":"Herz"},{"key":"R32-29-20210208","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/hc3601.095927","article-title":"Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial","volume":"104","author":"Devereux","year":"2001","journal-title":"Circulation"},{"key":"R33-29-20210208","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.amjhyper.2006.06.010","article-title":"Is echocardiography essential in the management of newly diagnosed hypertension?","volume":"19","author":"Bella","year":"2006","journal-title":"Am J Hypertens"},{"key":"R34-29-20210208","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/hc3901.096700","article-title":"Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril","volume":"104","author":"Mathew","year":"2001","journal-title":"Circulation"},{"key":"R35-29-20210208","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(98)09103-X","article-title":"Application of evidence from randomised controlled trials to general practice","volume":"353","author":"Rosser","year":"1999","journal-title":"Lancet"},{"key":"R36-29-20210208","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3317\/jraas.2006.044","article-title":"Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE Study","volume":"7","author":"Barrios","year":"2006","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R37-29-20210208","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1161\/01.HYP.7.1.105","article-title":"Five-year findings of the Hypertension Detection and Follow-up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy.","volume":"7","year":"1985","journal-title":"Hypertension"},{"key":"R38-29-20210208","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0002-9149(89)90286-5","article-title":"Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial","volume":"63","author":"MacMahon","year":"1989","journal-title":"Am J Cardiol"},{"key":"R39-29-20210208","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/CIRCULATIONAHA.105.574822","article-title":"Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study","volume":"113","author":"Okin","year":"2006","journal-title":"Circulation"},{"key":"R41-29-20210208","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/01.CIR.90.4.1786","article-title":"Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy","volume":"90","author":"Levy","year":"1994","journal-title":"Circulation"},{"key":"R42-29-20210208","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jacc.2004.11.046","article-title":"Cross-sectional relations of electrocardiographic QRS duration to left ventricular dimensions. The Framingham Heart Study","volume":"45","author":"Dhingra","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R43-29-20210208","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/01.HYP.36.5.766","article-title":"Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study","volume":"36","author":"Okin","year":"2000","journal-title":"Hypertension"},{"key":"R44-29-20210208","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1525-1497.2006.00397.x","article-title":"How do providers assess antihypertensive medication adherence in medical encounters?","volume":"21","author":"Bokhour","year":"2006","journal-title":"J Gen Intern Med"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004872-200709000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:55:44Z","timestamp":1786035344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004872-200709000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3282257145","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}